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Abstract 
Due to the unique opportunity to assess individuals before and after they develop depression 
within a short timeframe, interferon-alpha (IFN-α) treatment for chronic hepatitis C virus (HCV) 
infection is an ideal model to identify molecular mechanisms relevant to major depression, 
especially in the context of enhanced inflammation. 58 patients were assessed prospectively, at 
baseline and monthly over 24-weeks of IFN-α. New onset cases of depression were determined 
using the Mini International Neuropsychiatric Interview (MINI). Whole blood transcriptomic 
analyses were conducted to investigate: 1) baseline gene expression differences associated 
with future development of IFN-α-induced depression, before IFN-α; and 2) longitudinal gene 
expression changes from baseline to weeks 4 or 24 of IFN-α, separately in those who did and 
did not develop depression. Transcriptomics data were analysed using Partek Genomics Suite 
(1.4-fold, FDR adjusted p⩽0.05) and Ingenuity Pathway Analysis Software. Twenty patients 
(34%) developed IFN-α-induced depression. At baseline, 73 genes were differentially expressed 
in patients who later developed depression compared with those who did not. After 4 weeks of 
IFN-α, 592 genes were modulated in the whole sample, representing primarily IFN-α -
responsive genes. Substantially more genes were modulated only in patients who developed 
depression (n=506, compared with n=70 in patients who did not), with enrichment in 
inflammation-, neuroplasticity- and oxidative stress-related pathways. A similar picture was 
observed at week 24. Our data indicate that patients who develop IFN-α-induced depression 
have an increased biological sensitivity to IFN-α, as shown by larger gene expression changes, 
and specific signatures both as predictors and as correlates.  
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Introduction 
The development of clinically significant depression during interferon-alpha (IFN-α) therapy for 
chronic hepatitis C virus (HCV) infection is common, with an incidence of up to 45% (Asnis and 
De La Garza, 2006). Extensive research has been conducted to understand the biological 
systems involved in the development of IFN-α-induced depression, and to identify biological 
predictors associated with an enhanced risk to develop depressive symptoms. However, the 
molecular mechanisms are still unclear. Due to the unique opportunity to assess individuals 
before and after they develop depression within a short period of time (weeks rather than 
months or years), this model can also crucially identify mechanisms relevant to major 
depression at large, or at least in the context of increased inflammation. Previous studies have 
used hypothesis-based approaches, focussed on specific biomarkers (Capuron et al, 2003; 
Lotrich et al, 2013; Raison et al, 2009). However, IFN-α activates many biological systems, 
therefore a hypothesis-free approach may identify novel molecular mechanisms that predict or 
correlate with the development of depression. 
 
Peripherally, IFN-α acutely induces the production and release of other innate immune 
cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) (Raison et al, 
2008). These cytokines are putatively involved in the depressogenic action of IFN-α. Higher 
serum or plasma levels of these (and other) pro-inflammatory markers have been shown to be 
associated with an increased risk of major depressive disorder (Dowlati et al, 2010). Our own 
work has shown increased inflammation in the blood of depressed patients when compared to 
healthy controls together with an association between higher cytokine levels and lack of 
antidepressant response (Cattaneo et al, 2013). Post-mortem gene expression studies show an 
up-regulation of a variety of pro- and anti-inflammatory cytokines in the prefrontal cortex of 
depressed patients (Shelton et al, 2011), thus indicating that peripheral inflammation may 
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correlate with central abnormalities. However, the link between increased peripheral 
inflammation and IFN-α-induced depression is still unclear and studies report mixed results. For 
example, Wichers et al. (Wichers et al, 2006) report a difference in plasma levels of IL-6 levels 
between patients who develop IFN-α-induced depression and those who do not, but no 
difference in plasma levels of TNF-α. Conversely, Raison et al. report increased plasma 
concentrations of TNF-α to be significantly correlated with increased depression scores but no 
correlation was observed for IL-6 (Raison et al, 2008). 
 
A consolidated method to investigate the pathogenesis of psychiatric disorders is the use of 
peripheral blood to measure gene expression (mRNA) levels, which may be considered 
indicative of gene expression profiles in the brain (Hepgul et al, 2013). Several studies have 
shown that blood cells share more than 80% of the transcriptome with other tissues, including 
the brain (Liew et al, 2006). A comparison of the transcriptional profiling of 79 human tissues, 
showed that whole blood shares significant gene expression similarities with multiple brain 
tissues, in particular, for genes encoding for neurotransmitter receptors and transporters, stress 
mediators, cytokines, hormones and growth factors, all of which are relevant to depression 
(Sullivan et al, 2006). Global gene profiling in IFN-α-treated cells has shown a number of 
interferon-stimulated genes (Wang and Campbell, 2005) such as IFN-induced 15 kDa protein 
(ISG15), ubiquitin-specific proteinase 18 (USP18), IFN-induced 10kDA protein (IP-10 or 
CXCL10), signal transducers and activators of transcription (STAT1) and IFN-induced 
guanylate-binding protein 3 (GBP3), and again with similarities between immune and brain cells 
(Wang et al, 2008). Of specific relevance to the present study, to date only five studies have 
investigated peripheral blood gene expression changes in the development of IFN-α-induced 
depression. Three of these studies used a candidate gene approach, thus limiting the 
identification of novel or hitherto unknown mechanisms (Birerdinc et al, 2012; Krueger et al, 
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2011; Pawlowski et al, 2014), while two used transcriptomics (Felger et al, 2012; Schlaak et al, 
2012). Felger and colleagues used mRNA from isolated peripheral blood mononuclear cells 
(PBMCs) of 11 HCV patients before and after 12 weeks of IFN-α treatment (Felger et al, 2012). 
They found 252 up-regulated and 116 down-regulated genes after 12 weeks of IFN-α treatment. 
However, the sample size was small (only 4 patients developed depressive symptoms), and 
only two genes were found to be differentially expressed in patients with depression: the 2’-5’-
oligoadenylate synthetase 2 (OAS2; up-regulated), and the high affinity IgE receptor (FCER1A; 
down-regulated). In the other transcriptomics study, blood mRNA was examined 12 hours 
before and 12 hours after the first injection of IFN-α (Schlaak et al, 2012). IFN-α-induced 
depression (after at least 3 months of treatment) was found to be associated with up-regulation 
of 15 genes, suggesting that very early responses to IFN-α are related to the development of 
depression.  
 
In this study, we have used whole blood transcriptomics to investigate, in a large sample of HCV 
patients: 1) baseline gene expression differences associated with future development of IFN-α-
induced depression, before IFN-α administration; and 2) longitudinal changes in gene 
expression from baseline to treatment week 4 (TW4) and treatment week 24 (TW24) of IFN-α, 
separately in those who did and did not develop depression. In addition, a small number of 
candidate cytokines were assessed in the plasma of patients at the same time points.  
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Materials and Methods  
Study Design  
This was a prospective cohort study, evaluating patients at baseline and monthly over 24 weeks 
of IFN-α treatment. Blood samples for whole blood mRNA analysis were collected in PAXgene 
Blood RNA Tubes (PreAnalytiX, Switzerland) and for plasma cytokine measurement in 2ml 
K3EDTA tubes (ThermoFisher Scientific, Massachusetts, USA) using standard protocols, at 
baseline and at treatment weeks 4 (TW4) and 24 (TW24). We recruited 58 participants from the 
outpatient liver departments of three London hospitals: King’s College Hospital, Guy’s and St. 
Thomas’ Hospital and St. George’s Hospital. Eligible participants were adults with chronic HCV 
infection due to commence combination antiviral therapy with IFN-α and ribavirin for at least 24 
weeks; this comprised weekly subcutaneous IFN-α injections (1.5 μg per kg of body weight) and 
daily ribavirin tablets (800 to 1400 mg/day orally, in 2 divided doses). Exclusion criteria included: 
age below 18 years, current diagnosis (at baseline) of major depressive disorder, autoimmune 
disorder, current use of antidepressants, lack of English language, and co-infection with HIV or 
hepatitis B. Written informed consent was obtained from all participants. The research team did 
not interfere with usual clinical practice; when the research team detected depression 
development during IFN-α, this information was communicated to the treating hepatitis clinical 
team, who in turn decided whether or not to refer to liaison psychiatry services. The study was 
approved by the King’s College Hospital Research Ethics Committee (Ref: 10/H0808/30).  
 
Questionnaires, Clinical assessment and Sample Description 
The Mini International Neuropsychiatric Interview (MINI) was administered at baseline to assess 
current depression or a previous history of depression; and at follow-up assessments for the 
detection of new-onset cases of depression. The MINI is a structured diagnostic interview for 
psychiatric disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 4th 
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Edition (DSM-IV) and the International Statistical Classification of Diseases and Related Health 
Problems 10th Revision (ICD-10) (Sheehan et al, 1998). For the purpose of this study, we only 
focused on the detection and diagnosis of major depressive episode. Additionally, the severity 
of depressive symptoms was assessed using the Inventory of Depressive Symptomatology 
(IDS) (Rush et al, 1986). IDS scores were significantly higher at TW4 and TW24 when 
compared to baseline (20.8±1.7 vs. 11.6±1.5, p<0.001 and 22.9±2.0 vs. 11.6±1.5, p<0.001, 
respectively), while there was no significant difference between TW4 and TW24 (20.8±1.7 vs. 
22.9±2.0, p=0.2).  
 
The depressed group were defined by a MINI diagnosis of major depressive episode at any time 
point during the 24 weeks. Four (7%) patients developed depression by TW4, and a total of 20 
(34%) by TW24, while 38 patients (66%) did not develop depression. Two patients were started 
on antidepressant treatment after they developed IFN-α-induced depression. The socio-
demographic and clinical characteristics of the sample are presented in Table 1. Patients who 
developed depression were significantly more likely to have a previous history of depression, be 
unemployed and have higher baseline depression scores. These three variables were 
interrelated and indeed those with a history of depression were more likely to be unemployed 
and to have higher depression scores at baseline (data not shown). Given this interrelation, and 
the existing evidence for the presence of mood or anxiety symptoms prior to treatment as a risk 
factor (Dieperink et al, 2003; Lotrich et al, 2007), baseline depression scores were used as a 
covariate in all statistical analyses. 
 
RNA isolation and Transcriptomics analyses 
Isolation of total RNA was performed using the PAXgene blood miRNA kit according to the 
manufacturer’s protocol (PreAnalytiX, Hombrechtikon, CHE). RNA quantity and quality were 
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assessed by evaluation of the A260/280 and A260/230 ratios using a Nanodrop 
spectrophotometer (NanoDrop Technologies, Delaware, USA) and samples kept at -80°C until 
processing for whole genome transcriptomics analyses. Microarray assays were performed 
following protocol described in the Affymetrix GeneChip Expression Analysis technical manual 
(Affymetrix, California, USA). Briefly 250ng RNA were used to synthesize cDNA with the 
Ambion WT Expression Kit (ThermoFisher Scientific, Massachusetts, USA) which was then 
purified, fragmented, labelled and hybridized onto Human Gene 1.1 ST Array Strips (Affymetrix, 
California, USA). The reactions of hybridation, fluidics and imaging were performed on the 
Affymetrix GeneAtlas platform (Affymetrix, California, USA) instrument according to the 
manufacturer’s protocol. Validation of transcriptomics was performed using Real Time PCR (full 
details in Supplemental Materials). Correlation between the Affymetrix and Real Time values 
was 0.99 (data presented in Supplemental Table S1). 
 
Plasma cytokine measurement 
Blood samples were collected in 2ml K3EDTA tubes (ThermoFisher Scientific, Massachusetts, 
USA). On arrival to the laboratory, samples were centrifuged at 1500g for 15 minutes at room 
temperature, and plasma removed and frozen at -80°C until processing for cytokine 
measurement. All candidate proteins were measured utilizing Magnetic Luminex® Performance 
Multiplex Assay (R&D Systems Inc., Minneapolis, USA) using the customised 7-plex Human High 
Sensitivity Cytokine Premixed kit (R&D, FCSTM14). From the cytokines available for “high-
sensitivity” measurement, we chose five cytokines known to be stimulated by IFN-α (interleukin-1 
beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interferon-gamma (IFN-γ), and tumor 
necrosis factor-alpha (TNF-α) (Taylor and Grossberg, 1998)) and two that are inhibited 
(interleukin-7 (IL-7) (Su et al, 1997) and interleukin-17A (IL-17A) (Cui et al, 2014)). All samples 
were assayed according to the manufacturer’s protocol, and the results analyzed using SoftMax 
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Pro V4.8 (full details in Supplemental Materials). IFN-γ levels were below detection limit for most 
samples, therefore were not analysed further.  
 
Statistical and Bioinformatic Analyses 
Data were analyzed using IBM SPSS V20. Continuous variables are presented as mean±SEM. 
Differences in clinical and socio-demographic variables between patients who developed IFN-α-
induced depression and those did not were analysed using independent samples t-tests. 
Changes in depression scores between time points were analysed using paired samples t-tests. 
A repeated-measures ANCOVA (with baseline IDS scores as a covariate) was performed to test 
for differences in plasma cytokine levels as an effect of IFN-α treatment (time effect) and in 
relation to depression development (group effect). For gene expression data, CEL files were 
imported into Partek Genomics Suite V6.6 for data visualization and quality control. In summary 
(full details in Supplemental Materials), background correction was conducted using Robust 
Multi-strip Average (RMA) (Irizarry et al, 2003), and Quantile Normalization (Bolstad et al, 2003) 
was used to normalize the distribution of probe intensities among different microarray strips. 
Summarization was conducted using a linear median polish algorithm (Tukey, 1977) to integrate 
probe intensities and compute expression levels for each gene transcript. To assess the effect 
of IFN-α treatment, a multiple linear contrast over time was performed, and gene lists obtained 
by applying cut-offs of both p-value (FDR corrected) of ≤0.05 and a minimum absolute fold 
change of 1.4. Ingenuity Pathway Analysis (IPA) Software was used to identify regulation of 
molecular signalling pathways. 
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Results 
Baseline gene expression differences predicting the development of IFN-α-induced depression 
We first examined differences in gene expression at baseline (before starting IFN-α), and 
compared the profile of patients who subsequently did and did not develop IFN-α-induced 
depression. Using the above-mentioned cut-off criteria, and baseline depression scores as a 
covariate, we found 73 differentially modulated genes (See Supplemental Table S2). Pathway 
analysis of these 73 genes identified 24 pathways, including inflammation-, neuroplasticity- and 
oxidative stress-related pathways, such as interleukin-1 (IL-1) signalling, NRF2-mediated 
oxidative stress response and axonal guidance signalling. These pathways are presented in 
Figure 1 and Table 2. In addition, we also compared plasma cytokine levels at baseline 
however, there were no significant differences between the two groups (all p-values >0.2; see 
Supplemental Table S3). 
 
Genes modulated by IFN-α at treatment week 4, in the whole sample and in relation to 
development of IFN-α-induced depression 
We identified genes modulated by IFN-α by comparing the expression profile of the sample at 
TW4 with the profile at baseline. IFN-α modulated 592 genes, including well-known IFN-α 
targets, such as interferon alpha-inducible protein 27 (IFI27, FC=+32.05), interferon-induced 
protein 44-like (IFI44L, FC=+11.59), ubiquitin specific peptidase 18 (USP18, FC=+4.39), ISG15 
ubiquitin-like modifier (ISG15, FC=+2.70) and chemokine (C-X-C motif) ligand 10 (CXCL10, 
FC=+1.84). Subsequently, we investigated genes modulated by IFN-α separately in patients 
who developed depression (n=20) and those who did not (n=38). We found 506 genes 
modulated only in patients who developed depression (see Supplemental Table S4) and 70 
genes modulated only in patients who did not develop depression (see Supplemental Table 
S5). We focussed our further analyses on the 506 genes specifically modulated in patients who 
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developed depression. We found 224 up-regulated and 284 down-regulated genes, including 
genes previously found to be associated with depression, such as chemokine ligand 10 
(CXCL10, FC=+2.13) and insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2, 
FC=+1.88). Pathway analysis of these 506 genes identified 65 pathways, including those 
related to inflammation (IL-1, interleukin-6 (IL-6) and interleukin-8 (IL-8) signalling, 
glucocorticoid receptor signalling, triggering receptor expressed on myeloid cells 1 (TREM-1) 
signalling and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalling); 
neuroplasticity (extracellular-signal-regulated kinase 5 (ERK5) signalling and axonal guidance 
signalling); and oxidative stress (NRF2-mediated oxidative stress response, p53 signalling and 
production of nitric oxide and reactive oxygen species in macrophages). These pathways are 
presented in Figure 2 and Table 3. 
 
Finally, we conducted a two-way repeated measure ANCOVA (with baseline depression scores 
as a covariate) to investigate changes in plasma cytokine levels between TW4 and baseline, 
and also in relation with depression development. We found a significant effect of IFN-α (time 
effect) for decreasing IL-1β (p=0.043), and increasing IL-6 (p=0.013), IL-17A (p=0.022) and 
TNF-α (p<0.001) but no effect of depressive status (group effect, all p values >0.3) nor time by 
group effect (all p values >0.2) (see Supplemental Table S3). 
 
Genes modulated by IFN-α at week 24, in the whole sample and in relation to development of 
IFN-α-induced depression 
In order to assess whether IFN-α-modulated changes persisted further down the treatment 
course, we compared the gene expression profile of patients at TW24 with the profile at 
baseline. Similarly to TW4, modulation of several IFN-α-target genes were observed in the 
whole sample, including IFI27, (FC=+34.20), IFI44L, (FC=+11.78), USP18 (FC=+4.72), ISG15 
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(FC=+2.80) and CXCL10 (FC=+2.52). In addition, we observed modulation of other known IFN-
α-target genes which we did not see at TW4, such as guanylate binding protein 3 (GBP3, 
FC=+1.45) and signal transducer and activator of transcription 1, 91kDa (STAT1, FC=+1.45). 
We found 285 genes modulated only in patients who developed depression (see Supplemental 
Table S6) and 121 genes modulated only in patients who did not develop depression (see 
Supplemental Table S7). We focussed our further analyses on the 285 genes that were 
modulated in patients who developed depression. These included 215 up-regulated and 112 
down-regulated genes. Pathway analysis of these 285 genes identified 20 pathways. 
Interestingly, as indicated in Table 3, eight pathways were modulated at both TW4 and TW24, 
including ERK5 signalling, SAPK/JNK signalling and the Glutathione Redox Reactions I 
pathway. The full list of 20 pathways and their role classifications can be seen in Supplemental 
Table S8 and Supplemental Figure S9 respectively.  
 
Again, we conducted a two-way repeated measure ANCOVA (with baseline depression scores 
as a covariate) to investigate changes in plasma cytokine levels between TW24 and baseline, 
and in relation with depression development. We found a significant effect of IFN-α (time effect) 
for increasing IL-6 (p=0.012), IL-17A (p=0.008) and TNF-α (p<0.001), but again no effect of 
depressive status (group effect, all p values >0.4) nor time by group interaction (all p values 
>0.1) (see Supplemental Table S3). 
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Discussion 
To our knowledge, this is the first study to use a peripheral blood transcriptomics approach to 
identify both predictors of future development of IFN-α-induced depression and biological 
pathways associated with the development of depression. Already before IFN-α, patients who 
later develop depression show significant differences in the expression of several pathways 
compared with those who do not; and, by treatment week 4, they show specific longitudinal 
changes in similar and additional pathways, related to inflammation, neuroplasticity and 
oxidative stress. We replicate a number of previously identified interferon-responsive genes. For 
example, Wang and colleagues listed ISG15, USP18, IP-10/CXCL10, STAT1 and IFN-induced 
GBP3 as some of the most highly expressed interferon responsive genes (Wang et al, 2008), 
and we show changes in all of these genes following IFN-α administration. In addition, we 
replicate IFN-α-stimulated genes found in cultured neurons including IRF7, PNPT1 and IFIH1 
(Wang et al, 2005). Finally, we replicate 100 genes (35%), and 5 pathways, shown to be 
responsive to IFN-α by Felger et al. (Felger et al, 2012). These consistencies strengthen the 
validity of our findings. 
 
Among the most significant differentially expressed genes at baseline (predictors) we find up-
regulation of ubiquitin-fold modifier 1 (UFM1) and eukaryotic translation initiation factor 4B 
(EIF4B) in patients who later develop IFN-α-induced depression. The exact functions of UFM1 
are poorly understood, however it has been shown to be involved in heart disease (Azfer et al, 
2006) and diabetes (Lemaire et al, 2011) (conditions which present frequent comorbidity with 
depression), as well as schizophrenia (Rubio et al, 2013). EIF4B is a downstream component of 
the mammalian target of rapamycin (mTOR) signalling pathway. There is abundant evidence 
linking mTOR signalling to synaptic plasticity, memory and psychiatric disorders (Hoeffer and 
Klann, 2010). Whilst we see increased expression of EIF4B in our patients who subsequently 
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develop IFN-α-induced depression, Jernigen et al. report significant reductions in EIF4B (and 
mTOR) expression in the prefrontal cortex of depressed subjects (Jernigan et al, 2011). The 
sample used by Jerningen et al. were on overage more than 10 years older and were 
predominantly suicide victims which may account for these discrepant results. Also at baseline, 
we identified 24 pathways, some related to inflammation (IL-1 and CCR3 signalling), 
neuroplasticity (axonal guidance and netrin signalling) and oxidative stress (NRF2-mediated 
oxidative stress response and glutathione redox reactions I signalling). Some of these pathways 
were also significantly regulated longitudinally in patients who develop depression (see below).  
 
Following 4 weeks of IFN-α treatment, we find that the number of modulated genes is more than 
7 times larger in patients who develop depression than in patients who do not; suggesting that 
patients who develop IFN-α-induced depression have an increased biological sensitivity to IFN-
α. Of note, only 4 patients were depressed at treatment week 4 (TW4), while the majority 
became depressed between week 4 and 12 (n=11) or between week 12 and 24 (n=5); 
therefore, most patients classified as depressed in these analyses were on a trajectory to 
develop depression but had not yet developed it. As such, gene expression changes at TW4 
could be conceptualised as early biological changes associated with future depression 
development, rather than as a consequences of a depressive status. In this regard, our findings 
are consistent with those of Capuron et al. (5) and Schlaak et al. (Schlaak et al, 2012), who 
have demonstrated that cortisol responses, and, respectively, gene expression changes, after 
the first injection of IFN-α, predict the development of depression after 12 weeks of treatment. 
 
Our findings confirm and extend previous gene expression studies in patients with IFN-α-
induced depression. Felger et al. (Felger et al, 2012) used a different transcriptomics approach 
(isolated PBMCs and cross-sectional comparison at week 12). In relation to depression, they 
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found two genes differentially regulated in those who develop depression: OAS2 (up-regulated) 
and FCER1A (down-regulated). We also found that these two genes were regulated in the same 
direction by IFN-α; and found the change in OAS2 to be larger in patients who developed 
depression than in those who did not (FC=+4.13 versus FC=+3.06, respectively). Krueger et al. 
(Krueger et al, 2011), Beirderinc et al. (Birerdinc et al, 2012) and Pawlowski et al. (Pawlowski et 
al, 2014) all used a candidate gene approach focused on key immune genes only, and in 
smaller samples. They all found a variety of cytokines or cytokine-target genes differentially 
modulated in depressed patients. Although we do not directly replicate any of these specific 
genes, we find an involvement of several inflammatory pathways, including IL-6, IL-1, IL-8 and 
NF-κB. Finally, in their transcriptomics study, Schlaak et al. identified 15 genes regulated 12 
hours after the first injection of IFN-α in 11 patients who developed depression (in comparison to 
11 patients who did not develop depression) (Schlaak et al, 2012). Whilst we do not replicate 
these genes exactly, we find 5 genes belonging to the same family of genes (guanylate binding 
proteins, glutaredoxins, proteasome subunit beta type, tumor necrosis factor superfamily 
members and zinc finger proteins).  
 
Our pathway analysis data shows that patients who develop depression also exhibit modulation 
in oxidative stress pathways, such as NRF2-mediated oxidative stress response, the glutathione 
redox reactions I, and production of nitric oxide and reactive oxygen species in macrophages 
pathways. Glutathione plays an important role in detoxifying various reactive oxygen species 
which are known to induce oxidative stress (Franco et al, 2007). This finding is consistent with 
the evidence that depression is associated with increased oxidative and nitrosative stress, both 
in humans and animal models (Bakunina et al, 2015). We also demonstrate the involvement of 
neuroplasticity pathways such as extracellular-signal-regulated kinase 5 (ERK5) signalling. 
Indeed, major depressive disorder may involve a reduced ability of neuronal systems to show 
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adaptive plasticity, especially under stress conditions. There is a wealth of evidence indicating 
reductions in various neurotrophic factors in the plasma and serum, and more recently also in 
the gene expression, of depressed patients (Cattaneo et al, 2010; Dwivedi et al, 2005; Otsuki et 
al, 2008). ERK5 is a member of the mitogen-activated protein (MAP) kinase family that includes 
ERK1/2, p38, and Jun amino-terminal kinases (JNK), and participates in the neuronal 
modulation of depression (Todorovic et al, 2009). Indeed, the modulation of the ERK5 signalling 
pathway is accompanied by alterations in the stress-activated protein kinases (SAPK)/JNK 
signalling pathway in our patients who develop IFN-α-induced depression. Although ERK5 has 
not previously been implicated in the development of IFN-α-induced depression, activation of 
p38 MAPK in peripheral blood lymphocytes following the initial injection of IFN-α has been 
shown to be implicated (Felger et al, 2011). One mechanisms through which p38 MAPK can be 
depressogenic is by increasing the activity and expression of the serotonin transporter and by 
inhibiting glucocorticoid receptor (GR) function (Wang et al, 2004). This is in keeping with our 
finding for a modulation of the GR signalling pathway specifically in our depressed group. 
Reduced GR function (glucocorticoid resistance) coupled with high levels of cortisol is an 
indicator of hypothalamic-pituitary-adrenal (HPA) axis dysfunction and is one of the most 
replicated biological findings in depression, demonstrated also in gene expression studies 
(Matsubara et al, 2006). Glucocorticoid resistance has also been hypothesised to underlie the 
enhanced inflammation described in major depression (Pariante and Lightman, 2008).  
 
We also measured a small number of candidate cytokines in the plasma of our patients. Whilst 
we find a significant effect of IFN-α treatment in the whole sample, we do not detect any 
differences between patients who developed IFN-α-induced depression and those who did not. 
Indeed, previous studies examining peripheral inflammation and IFN-α-induced depression 
have produced inconsistent results. For example, as mentioned previously, Wichers et al. 
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(Wichers et al, 2006) report a difference in plasma IL-6 levels between patients who develop 
IFN-α-induced depression and those who do not, but no difference in plasma TNF-α levels. 
Conversely, Raison et al. report increased plasma TNF-α concentrations to be significantly 
correlated with increased depression scores but no correlation was observed for IL-6 (Raison et 
al, 2008). One study found no effect of IFN-α itself on plasma levels of key cytokines but instead 
found an increase in CSF concentrations (Raison et al, 2009). Although we found an effect of 
IFN-α on increasing IL-6, IL-17A and TNF-α, in general these studies and our findings confirm 
the notion that peripheral cytokines are not an accurate biomarker with reference to the effects 
of IFN-α. As such, we believe investigating gene expression is a more accurate and reliable 
method, and indeed none of the previous gene expression studies conducted in IFN-α-induced 
depression measured peripheral levels of cytokines. 
 
Our findings are both biologically and clinically relevant. Studying such a clearly defined patient 
group at “very-high-risk” of developing depression within a few weeks is a useful model to 
understand the pathogenesis of depression, especially depression in the context of enhanced 
inflammation, as it has been described after exposures to childhood trauma (Danese et al, 
2008), or due to  genetic predisposition (Bufalino et al, 2013). Of note, a recent transcriptomics 
study identified similar gene expression changes (in IL-6 and NF-κB signalling pathways) as 
correlates of antidepressant response to the TNF antagonist, infliximab, supporting the notion 
that our findings are relevant for this broader context (Mehta et al, 2013). There is also evidence 
that increased inflammation is associated with lack of antidepressant response (Cattaneo et al, 
2013; Guilloux et al, 2015), and therefore it is possible that the genes identified in our study are 
relevant to antidepressant response. Of note, in the context of HCV infection, biological 
predictors of IFN-α-induced depression can still have a role in clinical practice, even in light of 
emerging IFN-α free treatment regimens. At present, there are several drugs licenced for use in 
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HCV infection without IFN-α administration (Ryder, 2015); however, these treatments are not 
yet readily available for all viral genotypes and are highly expensive. As such, IFN-α-induced 
depression remains a clinical burden for some populations. 
 
There are some limitations of this study. Firstly, we acknowledge there are tissue-specific 
differences in gene expression patterns, and by using whole blood mRNA, we cannot 
understand which cell types are responsible for the changes we observe and how these may 
reflect changes in other tissues such as the brain. However, studies have shown a satisfactory 
degree of correlation between gene expression in the blood and gene expression the brain (Cai 
et al, 2010; Liew et al, 2006; Sullivan et al, 2006), and indeed, as mentioned above, we replicate 
(in peripheral blood) the pattern of interferon-responsive genes previously described in IFN-α 
stimulated neurons (Wang et al, 2005). Therefore, we believe that this issue does not detract 
from the impact our findings. Secondly, all of the patients received combination therapy with 
IFN-α and the antiviral agent ribavirin. Furthermore, although use of antidepressants was an 
exclusion criterion at baseline, a very small number of depressed patients were prescribed 
antidepressants during IFN-α (n=2). As such, there may be some transcriptional and 
behavioural changes that could have been influenced by these pharmacological agents.  
 
In conclusion, this study provides several lines of evidence for the possible molecular 
mechanisms involved in the impact of IFN-α on behaviour. Beyond IFN-α treatment, the 
identified transcriptomics signatures could be used as biomarkers for the identification of 
individuals at risk of developing depression, especially in the context of high inflammation due to 
stress, physical illness or genetic make-up, or to generate molecular targets for the discovery of 
new therapeutics in depression. 
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 Table 1 Socio-demographic and clinical characteristics of the sample 
 Whole 
Sample 
n = 58 
Depressed 
Patients 
n = 20 
Non-
Depressed 
Patients 
n = 38 
 
Age (years) 
Mean±SEM 
 
44.7±1.6 
 
42.4±2.5 
 
45.9±2.0 
 
t=1.1, df=56, p=0.3 
Gender 
Males 
 
45 (78%)
 
15 (75%) 
 
30 (79%) 
 
x2=0.12, p=0.5 
Ethnicity 
White British 
Other 
 
27 (47%)
31 (53%)
 
8 (40%) 
12 (60%) 
 
19 (50%) 
19 (50%) 
 
 
x2=0.53, p=0.3 
Education level 
University/A Levels 
GCSEs/No Qualifications 
 
23 (41%)
33 (59%)
 
8 (40%) 
12 (60%) 
 
15 (42%) 
21 (58%) 
 
 
x2=0.01, p=0.6 
Employment 
Full-time 
Unemployed 
 
32 (55%)
26 (45%)
 
7 (35%) 
13 (65%) 
 
25 (66%) 
13 (34%) 
 
 
x2=5.02, p<0.05 
Relationship status 
Single 
Married/Cohabiting 
 
27 (47%)
31 (53%)
 
8 (40%) 
12 (60%) 
 
19 (50%) 
19 (50%) 
 
 
x2=0.53, p=0.3 
History of depression 19 (33%) 10 (50%) 9 (24%) x2=4.12, p<0.05 
Family history of 
psychiatric illness 
 
14 (31%)
 
5 (36%) 
 
9 (29%) 
 
x2=0.20, p=0.5 
Baseline depression 
scores 
 
11.6±1.5 
 
16.1±3.0 
 
9.2±1.6 
 
t=-2.3, df=56, p<0.05 
TW4 depression scores 20.8±1.7 28.6±2.5 16.6±1.9 t=-3.8, df=56, p<0.001
TW24 depression scores 22.9±2.0 37.1±3.3 15.5±1.6 t=-6.7, df=56, p<0.001
Alcohol use 
Mean±SEM 
 
4.2±0.9 
 
5.3±2.1 
 
3.7±0.8 
 
t=-0.9, df=54, p=0.4 
HCV genotype   
1 & 4 
2 & 3 
 
13 (22%)
45 (78%)
 
6 (30%) 
14 (70%) 
 
7 (18%) 
31 (82%) 
 
 
x2=1.01, p=0.2 
HCV Viral load (million) 
Mean±SEM 
 
2.2±2.8 
 
2.1±0.7 
 
2.2±0.5 
 
t=0.2, df=54, p=0.8 
Fibroscan scores (kpa) 
Mean±SEM 
 
9.9±1.2 
 
11.1±2.7 
 
9.3±1.3 
 
t=-0.7, df=44, p=0.5 
 
  
 Table 2 Pathways differentially modulated at baseline between patients who develop 
depression compared to those who do not (p≤0.05) 
 
  
Pathway Molecules 
Ephrin B Signalling GNAT2,NCK2,ROCK1,GNG2 
Coagulation System A2M,PROS1,SERPIND1 
G alpha q Signalling RGS18,PPP3R1,ROCK1,GNG2 
Ephrin Receptor Signalling GNAT2,NCK2,ROCK1,GNG2 
NRF2-mediated Oxidative Stress Response DNAJC8,DNAJA2,GSTM3,GPX2 
Cardiac Hypertrophy Signalling PPP3R1,GNAT2,ROCK1,GNG2 
CCR3 Signalling in Eosinophils PLA2G10,ROCK1,GNG2 
Netrin Signalling PPP3R1,NCK2 
Axonal Guidance Signalling PPP3R1,GNAT2,NCK2,ROCK1,GNG2 
CXCR4 Signalling GNAT2,ROCK1,GNG2 
Actin Nucleation by ARP-WASP Complex NCK2,ROCK1 
Role of NFAT in Regulation of the Immune 
Response PPP3R1,GNAT2,GNG2 
RhoGDI Signalling GNAT2,ROCK1,GNG2 
Thrombin Signalling GNAT2,ROCK1,GNG2 
Integrin Signalling NCK2,ROCK1,LIMS1 
G Beta Gamma Signalling GNAT2,GNG2 
Signalling by Rho Family GTPases GNAT2,ROCK1,GNG2 
IL-1 Signalling GNAT2,GNG2 
Phospholipase C Signalling PPP3R1,PLA2G10,GNG2 
fMLP Signalling in Neutrophils PPP3R1,GNG2 
Androgen Signalling GNAT2,GNG2 
Extrinsic Prothrombin Activation Pathway PROS1 
Glutathione Redox Reactions I GPX2 
Relaxin Signalling GNAT2,GNG2 
 Table 3 Pathways differentially modulated at treatment week 4 specifically in patients who 
develop depression (p≤0.05) 
Pathway Molecules 
Aryl Hydrocarbon Receptor Signalling 
FOS, NCOR2, HSPB1, IL1B, ALDH1A1, 
NQO2, ALDH5A1, NFIA, MGST1, TFDP1, 
MGST3, NRIP1 
IL-6 Signalling 
FOS, A2M, HSPB1, IL1RN, IL1B, TNFAIP6, 
CD14, IL6R, AKT2, IL6ST 
ERK5 Signalling * 
FOS, SGK1, GNA12, WNK1, GAB1, 
MAP3K3, IL6ST 
Pentose Phosphate Pathway * TKT, PGD, TALDO1 
NRF2-mediated Oxidative Stress Response 
FOS, DNAJA4, DNAJC8, DNAJC6, GCLC, 
ABCC4, DNAJA2, DNAJC15, NQO2, 
MGST1, MGST3 
Phenylethylamine Degradation I * ALDH2, AOC3 
NF-KB Signalling 
BMPR2, TNFSF13B, IL1RN, IL1B, AZI2, 
TLR6, PELI1, AKT2, MAP3K3, PLCG2 
LXR/RXR Activation 
NCOR2, S100A8, IL1RN, IL1B, MMP9, 
ORM1, CD14, PTGS2 
Ephrin B Signalling 
ACP1, EPHB4, GNAT2, GNA12, ROCK1, 
GNG2 
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages 
FOS, IFNGR1, NCF4, S100A8, ORM1, 
NCF1, SIRPA, AKT2, MAP3K3, PLCG2 
IL-8 Signalling 
FOS, MMP9, CXCR2, PTGS2, CXCR1, 
GNA12, ROCK1, BCL2L1, GNG2, AKT2 
Phosphatidylglycerol Biosynthesis II (Non-
plastidic) ABHD5, AGPAT9, PGS1 
Glucocorticoid Receptor Signalling 
KAT2B, NCOR2, IL1B, PPP3CA, AKT2, 
FOS, A2M, IL1RN, DUSP1, SGK1, PTGS2, 
BCL2L1, NRIP1 
Pentose Phosphate Pathway (Non-oxidative 
Branch) * TKT, TALDO1 
Rapoport-Luebering Glycolytic Shunt BPGM, MINPP1 
Glutathione Redox Reactions I * CLIC2, MGST1, MGST3 
Fatty Acid alpha-oxidation ALDH1A1, PTGS2, ALDH2 
 Pancreatic Adenocarcinoma Signalling * 
NOTCH1, MMP9, PTGS2, E2F2, BCL2L1, 
TFDP1, AKT2 
RAR Activation 
FOS, KAT2B, NCOR2, RPL7A, PML, 
DUSP1, ALDH1A1, AKT2, NRIP1, 
PRKAR1A 
Superpathway of Inositol Phosphate 
Compounds 
PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, 
SIRPA, PPP3CA, MINPP1, INPP5A, 
PLCG2 
Pyrimidine Deoxyribonucleotides De Novo 
Biosynthesis I AK5, NME4, RRM2B 
Role of Macrophages, Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis 
TNFSF13B, F2RL1, IL1B, IL6R, PPP3CA, 
AKT2, IL6ST, PLCG2, FOS, IL1RN, C5AR1, 
ROCK1, TLR6 
G Beta Gamma Signalling 
GNAT2, GNA12, GNG2, AKT2, PLCG2, 
PRKAR1A 
Eicosanoid Signalling 
CYSLTR2, DPEP2, PTGS2, FPR2, 
TBXAS1 
Colorectal Cancer Metastasis Signalling 
FOS, IFNGR1, MMP9, PTGS2, IL6R, 
BCL2L1, TLR6, GNG2, AKT2, IL6ST, 
PRKAR1A 
D-myo-inositol-5-phosphate Metabolism 
PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, 
SIRPA, PPP3CA, PLCG2 
Granulocyte Adhesion and Diapedesis 
HSPB1, IL1RN, IL1B, MMP9, CXCL10, 
C5AR1, CXCR2, FPR2, HRH2 
Superpathway of D-myo-inositol (1,4,5)-
trisphosphate Metabolism IMPA2, MINPP1, INPP5A 
Prostanoid Biosynthesis PTGS2, TBXAS1 
PPAR Signalling FOS, NCOR2, IL1RN, IL1B, PTGS2, NRIP1 
EIF2 Signalling * 
RPL5, RPL7A, RPL13A, EIF4A1, RPL41, 
RPS2, AKT2, RPS15, AGO4 
p53 Signalling 
KAT2B, PML, BCL2L1, AKT2, RRM2B, 
PMAIP1 
Agranulocyte Adhesion and Diapedesis 
IL1RN, IL1B, MMP9, CXCL10, C5AR1, 
CXCR2, CXCR1, AOC3, MYH9 
Toll-like Receptor Signalling FOS, IL1RN, IL1B, CD14, TLR6 
Cholecystokinin/Gastrin-mediated Signalling FOS, IL1RN, IL1B, PTGS2, GNA12, 
 ROCK1 
D-myo-inositol (1,4,5,6)-Tetrakisphosphate 
Biosynthesis 
PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, 
SIRPA, PPP3CA 
D-myo-inositol (3,4,5,6)-tetrakisphosphate 
Biosynthesis 
PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, 
SIRPA, PPP3CA 
Cardiac Hypertrophy Signalling 
HSPB1, GNAT2, GNA12, IL6R, ROCK1, 
GNG2, PPP3CA, MAP3K3, PLCG2, 
PRKAR1A 
Sorbitol Degradation I SORD 
TREM1 Signalling NLRP12, IL1B, TLR6, AKT2, PLCG2 
Pyrimidine Ribonucleotides Interconversion ENTPD1, AK5, NME4 
Axonal Guidance Signalling 
MMP9, EPHB4, ADAM8, GNAT2, 
ARHGEF12, GNA12, TUBG1,PLXNC1, 
ADAM19, PPP3CA, AKT2, PLCG2, 
PRKAR1A, TUBA1A, ROCK1, GNG2 
HGF Signalling 
FOS, PTGS2, GAB1, AKT2, MAP3K3, 
PLCG2 
Molecular Mechanisms of Cancer 
NOTCH1, GNAT2, ARHGEF12, GNA12, 
GAB1, AKT2, PRKAR1A, FOS, RALB, 
BMPR2, E2F2, BCL2L1, TFDP1, PMAIP1 
Relaxin Signalling 
FOS, MMP9, GNAT2, GNA12, GNG2, 
AKT2, PRKAR1A 
Pyrimidine Ribonucleotides De Novo 
Biosynthesis ENTPD1, AK5, NME4 
Acute Phase Response Signalling 
FOS, A2M, IL1RN,I L1B, ORM1, IL6R, 
AKT2, IL6ST 
Role of NFAT in Regulation of the Immune 
Response 
FOS, SYK, GNAT2, GNA12, GNG2, 
PPP3CA, AKT2, PLCG2 
Xenobiotic Metabolism Signalling 
NCOR2, GCLC, IL1B, ALDH1A1, UGT2B7, 
NQO2, ALDH5A1, MGST1, MAP3K3, 
MGST3, NRIP1 
3-phosphoinositide Degradation 
PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, 
SIRPA, PPP3CA 
Triacylglycerol Biosynthesis ABHD5, AGPAT9, LPPR2 
Communication between Innate and 
Adaptive Immune Cells TNFSF13B, IL1RN, IL1B, CXCL10, TLR6 
 Cardiolipin Biosynthesis II PGS1 
GM-CSF Signalling CSF2RA, BCL2L1, PPP3CA, AKT2 
G alpha i Signalling 
RALB, CXCR2, FPR2, P2RY14, GNG2, 
PRKAR1A 
Aldosterone Signalling in Epithelial Cells 
HSPB1, DNAJC8, DNAJC6, DUSP1, SGK1, 
DNAJC15, PLCG2 
CDP-diacylglycerol Biosynthesis I ABHD5, AGPAT9 
Histamine Degradation ALDH1A1, ALDH2 
IL-1 Signalling FOS, GNAT2, GNA12, GNG2, PRKAR1A 
RhoA Signalling 
LPAR6 ,ARHGEF12, GNA12, ROCK1, 
CDC42EP2, ARHGAP9 
Cell Cycle: G1/S Checkpoint Regulation RPL5, E2F2, NRG1, TFDP1 
Salvage Pathways of Pyrimidine 
Ribonucleotides SGK1, AK5, CDK8, NME4, AKT2 
Atherosclerosis Signalling 
S100A8, TNFRSF14, IL1RN, IL1B, MMP9, 
ORM1 
Docosahexaenoic Acid (DHA) Signalling IL1B, BCL2L1, AKT2 
SAPK/JNK Signalling * MAP4K5, GNA12, GNG2, GAB1, MAP3K3 
Aryl Hydrocarbon Receptor Signalling 
FOS, NCOR2, HSPB1, IL1B, ALDH1A1, 
NQO2, ALDH5A1, NFIA, MGST1, TFDP1, 
MGST3, NRIP1 
 * Pathways which were also modulated at treatment week 24 
  
 Figure 1 Role classification of pathways differentially modulated at baseline between 
patients who develop depression compared to those who do not 
 
Figure 2 Role classification of pathways differentially modulated at treatment week 4 
specifically in patients who develop depression 


